Sponsor safety letters and CIOMS/MedWatch reports — Safety Reporting and Pharmacovigilance for CRCs

Free Lesson Preview

This is just the beginning

The full CRC track covers 8 courses from study start-up to close-out — the skills sponsors actually look for.

Already enrolled? Sign in

The receiving end of the pharmacovigilance system

In a Phase III trial with 200 sites spread across 30 countries, each investigating site may receive between 50 and 200 individual IND safety reports over the course of the study. Some sites in long-running cardiovascular or oncology trials report receiving significantly more. Each of those reports describes a serious adverse event that occurred at another site -- an event the sponsor has determined to be both unexpected and suspected to be drug-related. Each report requires investigator review. Each requires acknowledgment. Each must be filed. And some -- the ones that change what you know about the drug's safety profile -- require action.

This is the receiving end of the pharmacovigilance system. In Module 5, you learned how to generate safety reports -- identifying serious adverse events at your site, reporting them to the sponsor within 24 hours, following up until resolution. Now the cycle comes back to you. The sponsor has aggregated safety data from every site in the program, identified events that meet SUSAR criteria, and sent that information back to every investigator. Your site is one of those recipients. The question is not whether these communications will arrive. It is whether you will process them with the rigor they demand -- or whether they will accumulate in a binder, acknowledged in signature but not in substance.

I have seen both approaches. The difference is not subtle. A site that processes safety communications systematically catches the report that describes a safety signal relevant to three currently enrolled participants. A site that batch-signs them without reading catches nothing until the monitor asks why the investigator signed 47 IND safety reports on the same date with the same timestamp.